Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease

BACKGROUND: The FDA have recently published draft guidance for the development of treatments for early Alzheimer’s disease. Key features of this guidance are the advocacy of sensitive cognitive measures and a taxonomy of disease severity. Whilst desirable patterns of cognitive-functional improvement...

Descripción completa

Detalles Bibliográficos
Autor principal: Harrison, John E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026341/
https://www.ncbi.nlm.nih.gov/pubmed/29958538
http://dx.doi.org/10.1186/s13195-018-0386-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026341/
https://www.ncbi.nlm.nih.gov/pubmed/29958538
http://dx.doi.org/10.1186/s13195-018-0386-7

Ejemplares similares